Literature DB >> 1573523

Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients: treatment with fluconazole.

R Laroche1, B Dupont, J E Touze, H Taelman, J Bogaerts, A Kadio, P M'Pele, A Latif, P Aubry, J P Durbec.   

Abstract

Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) is particularly common in tropical Africa. This could be explained by the dramatic increase in the number of human immunodeficiency virus (HIV) infections and the high prevalence of Cryptococcus neoformans var. neoformans in the domestic and general environment of HIV-positive and AIDS patients Meningoencephalitis is the usual and dominant clinical feature of cryptococcal infection in AIDS patients and 'slim disease', tuberculosis and candidiasis are the most common opportunistic infections associated with cryptococcal meningitis. In a group of 64 African patients with AIDS and cryptococcosis treatment with a daily dose of 400 mg fluconazole (FCA) during the acute phase showed a clinical cure in 63% of the evaluable patients. Mycological response to treatment with negative culture was found in 76% of our patients (at day 60-90). The overall tolerance of FCA was excellent. This treatment was also used successfully for relapse of cryptococcal meningitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573523     DOI: 10.1080/02681219280000091

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  5 in total

1.  A vitamin-free minimal synthetic medium for Cryptococcus neoformans.

Authors:  V Vidotto; S Aoki; G Campanini
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

Review 2.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans.

Authors:  J W Murphy; M R Hidore; S C Wong
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 4.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

5.  Neuromeningeal cryptococcosis in sub-Saharan Africa: Killer disease with sparse data.

Authors:  Komi Assogba; Mofou Belo; Majeste Ihou Wateba; Dieu Donné Gnonlonfoun; Paul M Ossou-Nguiet; Berenger B C Tsanga; Moustapha Ndiaye; Eric K Grunitzky
Journal:  J Neurosci Rural Pract       Date:  2015 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.